

### REMARKS

Claims 18, 23-25 and 39 are pending in the application after entry of the above claim amendments. Claim 39 stands allowed. Claims 19, 26, 28, 29 and 31 have been cancelled by the herein amendment, and claims 18, 23, 24 and 25 have been amended. All claim amendments and cancellations are made without prejudice to the filing of one or more continuing applications. Reconsideration is requested in view of the above changes and the following remarks.

#### Consideration and Entry of This Amendment is Proper after Final Rejection

Based upon Examiner's guidance provided in the pending office action, it is believed that the above claims amendments will put the application in condition for allowance. This paper does not raise new issues for examination, and in fact serves to resolve all outstanding issues for examination. Accordingly, consideration and entry of this paper is believed proper notwithstanding the finality of the pending office action.

#### Response to Specification Objection

Reference to the websites formerly present at pages 16 and 17 of the specification have been removed.

#### Response to Section 112 Rejections

Claims 18 and 23-26 remain rejected under Section 112. Claim 26 has been cancelled. The amendment to claim 18 is believed to overcome all grounds of rejection under Section 112. In particular, claim 18 has been amended according to Examiner's suggestion to change "monoclonal antibody produced *from* a hybridoma cell" to "monoclonal antibody produced *by* a hybridoma cell". Also, claims 23-25 have been amended pursuant to Examiner's suggestion for rewriting those claims in terms of a "composition comprising" a monoclonal antibody. Accordingly, claims 18 and 23-25 are free of all remaining rejections under Section 112.

#### Response to Section 102 and 103 Rejections

Claims 18 and 23-26 have been rejected for anticipation over Shearman *et al.*, or obviousness over Shearman *et al.* in view of Monia *et al.* Claim 26 has been cancelled. The


amendment to claims 18 overcomes the asserted grounds of rejection against claims 18 and 23-25.

Conclusion

The claims remaining in the application are believed to be in condition for allowance. An early action toward that end is earnestly solicited.

Examiner is encouraged to telephone the undersigned if further action or amendment by applicants is necessary to progress the application to allowance.

Respectfully submitted,  
KARL MULLIGAN *et al.*

BY   
DANIEL A. MONACO  
Registration No. 30,480  
DRINKER BIDDLE & REATH LLP  
One Logan Square  
18<sup>th</sup> and Cherry Streets  
Philadelphia, PA 19103-6996  
TEL.: (215) 988-3312  
FAX: (215) 988-2757  
*Attorney for Applicants*